HER2-POSITIVE BREAST CARCINOMA

This study tests a new drug (TVB-2640) combined with standard treatments for people with HER2+ breast cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors or slow the disease. About 17 adults with advanced brea…

This phase 3 trial tests whether adding tucatinib to the standard drug T-DM1 can better prevent HER2-positive breast cancer from returning in high-risk patients. About 1,056 participants who still have cancer after initial treatment will receive either T-DM1 alone or T-DM1 plus t…

This early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…

This study tests a combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. About 46 women with advanced …

This study tests whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to targeted drugs (trastuzumab and pertuzumab) before surgery. About 18 women with locally advanced breast cancer will receive the scan and the…

This study tests whether a special PET/CT scan (FDG-PET/CT) can predict how well HER2-positive breast cancer responds to chemotherapy before surgery. About 235 adults with stage II-III breast cancer will get the scan early in treatment. The goal is to see if the scan can help doc…

This study tests two different vaccines in people who had HER-2 positive breast cancer and still had cancer cells after initial treatment. The goal is to see if the vaccines are safe and can help prevent the cancer from coming back. Participants receive a series of vaccine shots …

This study looks at a blood test that finds tiny bits of tumor DNA in the blood of people with early-stage breast cancer. The goal is to see if this test can tell who still has cancer cells after treatment and might need more therapy. About 350 adults with stage I-III breast canc…

This early-phase trial looks at how DS-8201a works in patients with advanced HER2-positive solid tumors that have spread or cannot be removed. The drug targets a protein on cancer cells to damage their DNA and kill them. Researchers will compare tumor samples taken before and aft…